Favrille has completed enrollment in the pivotal Phase III clinical trial of FavId. Initiated in July 2004, the registration trial is designed to evaluate FavId following Rituxan therapy for the treatment of follicular B-cell non-Hodgkin's lymphoma (NHL).

The randomized, double-blind, placebo-controlled trial has been conducted at 67 oncology centers across the U.S. The trial has enrolled a much broader patient population than previous immunotherapy trials, and included both treatment-naive and relapsed/refractory patients with stable or responding disease following treatment with Rituxan. Approximately 80 percent of the patients enrolled are treatment-naïve, with the remainder either relapsed from or refractory to prior therapies.